Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?

Axsome Therapeutics (AXSM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 23, might help the stock move higher if these key numbers are better ...